This expansion adds three additional targets to the original agreement inked in December of 2007.

Galapagos expanded its antibacterials and antivirals partnership with GlaxoSmithKline to include three more discovery targets. For this expansion, Galapagos receives a payment from GSK of €2 million cash ($2.6 million). 

Under the terms of the alliance, Galapagos could be eligible to receive up to €95 million ($124.8 million) in up-front fees, and development and regulatory milestones payments for each product candidate. If a product is commercialized, Galapagos may receive up to €120 million ($157.6 million) for achievement of specific sales milestones. Galapagos is also eligible to receive up to double-digit royalties on worldwide sales of alliance products.

In December 2007, GSK and Galapagos initiated a program to discover and develop anti-infective drug candidates for GSK’s Infectious Diseases Centre of Excellence in Drug Discovery (ID CEDD). Galapagos is responsible for the discovery and development of natural product drug candidates through to clinical proof of concept, at which point GSK will have an exclusive option to license each compound for further development and commercialization on a worldwide basis. This agreement further broadens the scope of the alliance between the two companies through the nomination of three additional GSK targets. 


Previous articleResearchers Find Proteins Key to the Spread of Malaria
Next articleFAK Signaling Required for Ras- and PI3K-Dependent Breast Tumorigenesis